Mundipharma Research Limited

Quick facts

Marketed products

• Flixotide · Oncology

Phase 3 pipeline

• Flixotide plus Foradil · Respiratory/Pulmonology
  Flixotide plus Foradil is a combination inhaler that delivers a corticosteroid (fluticasone) to reduce airway inflammation and a long-acting beta-2 agonist (formoterol) to relax airway smooth muscle.
• Flixotide pMDI 250 micrograms · Respiratory / Pulmonology
  Fluticasone propionate is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.
• Fluticasone/formoterol BAI · Respiratory/Pulmonology
  Fluticasone/formoterol combines a corticosteroid that reduces airway inflammation with a long-acting beta-2 agonist that relaxes airway smooth muscle to improve breathing.
• Flutiform · Other
• Flutiform 250/10 micrograms · Respiratory/Pulmonology
  Flutiform combines fluticasone propionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma.
• Flutiform 50/5 micrograms · Respiratory/Pulmonology
  Flutiform combines fluticasone propionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma.
• Rezafungin for Injection · Infectious Disease
  Rezafungin is an echinocandin antifungal that inhibits fungal cell wall synthesis by targeting 1,3-beta-D-glucan synthase.

Phase 2 pipeline

• BTDS

Phase 1 pipeline

• First generation BuTrans patch
• IR morphine sulphate
• MR1XXX
• MR2XXX
• MR3XXX
• MR902
• MRXXX
• MRXXX and MR1XXX
• Second generation BTDS patch

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Mundipharma Research Limited portfolio CI brief
• Mundipharma Research Limited pipeline updates RSS